Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:Ranitidine
|
| gptkbp:activities |
inhibits gastric acid secretion
|
| gptkbp:approves |
gptkb:1988
gptkb:FDA |
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Axid_AR
Axid |
| gptkbp:category |
B
|
| gptkbp:class |
gptkb:drug
H2 receptor antagonist antiulcer agent |
| gptkbp:clinical_trial |
Phase III trials
Phase I trials Phase II trials |
| gptkbp:contraindication |
hypersensitivity to nizatidine
|
| gptkbp:developed_by |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
oral tablet
oral solution sustained-release tablet |
| https://www.w3.org/2000/01/rdf-schema#label |
Nizatidine
|
| gptkbp:indication |
prevention of ulcers
treatment of Zollinger-Ellison syndrome |
| gptkbp:ingredients |
C12 H21 N5 O2 S
|
| gptkbp:interacts_with |
gptkb:ketoconazole
gptkb:procainamide gptkb:theophylline gptkb:warfarin |
| gptkbp:is_available_on |
gptkb:product
gptkb:tablet |
| gptkbp:is_used_for |
treatment of gastroesophageal reflux disease (GERD)
treatment of ulcers |
| gptkbp:lifespan |
1-2 hours
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
Axid
|
| gptkbp:metabolism |
liver
|
| gptkbp:pharmacokinetics |
peak plasma concentration in 1-2 hours
rapid absorption bioavailability of 70% |
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
dizziness
fatigue headache muscle pain nausea confusion diarrhea rash constipation liver enzyme elevation |
| gptkbp:social_structure |
amino group
hydroxyl group thiazole ring imidazole ring sulfonamide group |
| gptkbp:type_of |
76963-41-2
|